Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Die Bedeutung von klinischen Tumorregistern.

Marschner, N., Kaiser-Osterhues, A., 2017.

Im Focus Onkologie 20(9), 42–44. doi:10.1007/s15015-017-3513-6

Indikation: Other, Sonstige / Veranstaltung: - / Journal: Im Focus Onkologie
Registerübergreifend
2017
Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer – final results from the prospective German TLK cohort study.

Verschuer, U. von, Schnell, R., Tessen, H.W., Eggert, J., Binninger, A., Spring, L., Jänicke, M., Marschner, N., 2017.

Lung Cancer. 2017 Aug 22. pii: S0169-5002(17)30419-1. doi: 10.1016/j.lungcan.2017.07.031

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: - / Journal: Lung Cancer
TLK
2017
Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – results from the prospective German TMK cohort study.

Fietz, T., Tesch, H., Rauh, J., Boller, E., Kruggel, L., Jänicke, M., Marschner, N., 2017.

The Breast 34, 122–130. doi:http://dx.doi.org/10.1016/j.breast.2017.05.014

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: The Breast
TMK
2017
Predicting early treatment discontinuation and effectiveness in bevacizumab-treated patients with advanced ovarian cancer: Exploratory analyses of the OTILIA study (on behalf of NOGGO)

Wimberger, P., Woopen, H., Mustea, A., Oskay-Oezcelik, G., Keller, M., Harde, J., Richter, R., Wegenaer, A., Klawitter, S., Tomé, O., Sehouli, J., 2017.

ESGO7–0321 (PS19)

Abstract

Indikation: Other, Sonstige / Veranstaltung: ESGO / Journal: -
OTILIA
2017
Routine clinical use of nab-paclitaxel for advanced / metastatic breast cancer in Germany: Final results of the prospective observational study NABUCCO.

Schroeder, J., Potthoff, K., Salat, C., Soeling, U., Hansen, R., Grebhardt, S., Harde, J., Nusch, A., Marschner, N., 2017.

J Clin Oncol 35(suppl; abstr e12555). doi:10.1200/JCO.2017.35.15_suppl.e12555

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
NABUCCO
2017
Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer – results from the MaTox project.

Hurtz, H.-J., Tesch, H., Göhler, T., Hutzschenreuter, U., Harde, J., Kruggel, L., Jänicke, M., Marschner, N., TMK-Group (Tumour Registry Breast Cancer), 2017.

Breast Cancer Res Treat. 2017 Jul 5. doi: 10.1007/s10549-017-4365-7

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Breast Cancer Research and Treatment
TMK
2017
The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape.

Goebell, P.J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehneß, R., Welslau, M., 2017.

Future Oncol 0(0). doi:10.2217/fon-2017-0083 (epup ahead of print)

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: - / Journal: Future Oncology
PAZOREAL
2017
Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer – Results from the prospective German Tumour Registry Breast Cancer cohort study.

Schröder, J., Fietz, T., Köhler, A., Petersen, V., Tesch, H., Spring, L., Fleitz, A., Jänicke, M., Marschner, N., 2017.

Eur J Cancer 79, 139–148. doi:10.1016/j.ejca.2017.03.031

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: European Journal of Cancer
TMK
2017
Clinical Research Platform into Molecular Testing, Treatment, Outcome (CRISP): A Prospective German Registry in Stage IV NSCLC AIO-TRK-0315.

Griesinger, F., Eberhardt, W., Marschner, N., Jänicke, M., Hipper, A., Karatas, A., Sebastian, M., Thomas, M., Schirmacher, P., 2017.

J Thorac Oncol 12(1)(MA08.02), S385. doi:10.1016/j.jtho.2016.11.435

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ELCC (IASLC) / Journal: Journal of Thoracic Oncology
CRISP
2017
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.

Schimanski, C.C., Staib, F., Göhler, T., Hebart, H., Heike, M., Neise, M., Rudi, J., Geer, T., Dingeldein, G., Lang, C., Ehscheidt, P., Flohr, T., Josten, K.M., Karthaus, M., Schmittel, A., Wierecky, J., Boller, E., Indorf, M., Wörns, M.-A., Galle, P.R., Moehler, M., 2017.

J. Cancer Res. Clin. Oncol. 143(6), 1023–1034. doi:10.1007/s00432-017-2344-3

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: Journal of Cancer Research and Clinical Oncology
DERMATUX
2017